FORM 20-F Grupo Casa Saba, S.A.B. de C.V.
FORM 20-F Grupo Casa Saba, S.A.B. de C.V.
FORM 20-F Grupo Casa Saba, S.A.B. de C.V.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Table of Contents<br />
This division represented 16.36% of the Company’s net sales in the <strong>20</strong>10 fiscal year.<br />
Gross Profit. <strong>Grupo</strong> <strong>Casa</strong> <strong>Saba</strong>’s gross profit totaled Ps. 4,527.8 million for the year en<strong>de</strong>d December 31, <strong>20</strong>10, an increase of 40.4% as compared to Ps. 3,225.8 million<br />
for the same period in <strong>20</strong>09. The improvement in the gross margin, which was 13.38% for the year en<strong>de</strong>d December 31, <strong>20</strong>10, as compared to 10.83% registered during the previous year,<br />
was primarily the result of higher margin sales from our Retail Pharmacy operations. FASA’s gross margin for <strong>20</strong>10 was 24.7% which, due to the nature of the business, is higher than<br />
the margins in the distribution business.<br />
Operating Expenses. Our operating expenses totaled Ps. 3,853.1 million for the year en<strong>de</strong>d December 31, <strong>20</strong>10, an increase of 65.01% as compared to Ps. 2,335.1 million<br />
for the year en<strong>de</strong>d December 31, <strong>20</strong>09. This was mainly the result of the incorporation of FASA into our retail operations given that operating expenses, such as store rents, are<br />
generally higher in the retail business than they are in distribution due to the nature of the operations. Therefore, this figure is not comparable with the previous year. Consequently,<br />
operating expenses represented 11.39% of our total net sales for the year en<strong>de</strong>d December 31, <strong>20</strong>10.<br />
Operating Income. Operating income for the year en<strong>de</strong>d December 31, <strong>20</strong>10 was Ps. 674.7 million, a <strong>de</strong>crease of 24.3% as compared to Ps. 890.7 million for the year<br />
en<strong>de</strong>d December 31, <strong>20</strong>09. This was due to the increase in our operating expenses, as <strong>de</strong>scribed above. As a result, our operating margin for year en<strong>de</strong>d December 31, <strong>20</strong>10 was 1.99%,<br />
compared to the margin of 2.99% for the year en<strong>de</strong>d December 31, <strong>20</strong>09.<br />
Comprehensive Financing Cost, Net. Pursuant to Mexican FRS, we report four items within this line item: interest expense, interest income, foreign exchange (gain)<br />
loss and the (gain) loss on net monetary position. Foreign exchange losses (or gains) arise primarily from U.S. Dollar-<strong>de</strong>nominated position or loans as the Peso <strong>de</strong>values or appreciates<br />
against the U.S. Dollar. The gain or loss on the net monetary position reflects the effect of inflation on monetary assets and liabilities. Monetary gains arise from holding a net<br />
monetary liability position during periods of inflation, while monetary losses arise from holding a net monetary asset position during periods of inflation. Since January 1, <strong>20</strong>08 we<br />
ceased inflation accounting pursuant to Mexican FRS.<br />
Our <strong>20</strong>10 comprehensive financing cost, net remained the same as the previous year, at Ps. 262.2 million for both the year en<strong>de</strong>d December 31, <strong>20</strong>09 and for the year<br />
en<strong>de</strong>d December 31, <strong>20</strong>10. This increase was the result of the rise in our interest expense, which totaled Ps. 493.0 million in <strong>20</strong>10, related to the acquisition of FASA compared to Ps.<br />
264.5 million in <strong>20</strong>09. However, this increase was partially offset by higher interest income earned, in the amount of Ps. 199.4 million, compared to Ps. 5.1 million in <strong>20</strong>09, as well as an<br />
exchange rate gain of 31.4 million as discussed in our consolidated statement of income.<br />
Tax Provisions. Provisions for taxes for the year en<strong>de</strong>d December 31, <strong>20</strong>10 was Ps. 48.3 million, a <strong>de</strong>crease of 77.2% as compared to Ps. 211.9 million for the year<br />
en<strong>de</strong>d December 31, <strong>20</strong>09. Income tax for the year en<strong>de</strong>d December 31, <strong>20</strong>10 amounted to Ps. 386.4 million, 12.42% greater than the income tax provisions for the year en<strong>de</strong>d December<br />
31, <strong>20</strong>09, and which was partially offset by the <strong>de</strong>ferred income tax of Ps. 338.0 million.<br />
Net Income. The Group’s net income for the year en<strong>de</strong>d December 31, <strong>20</strong>10 amounted to Ps. 270.0 million, a <strong>de</strong>crease of 3.6% as compared to Ps. 280.2 million for the<br />
year en<strong>de</strong>d December 31, <strong>20</strong>09. This <strong>de</strong>cline was primarily due to the increase in our operating expenses which was not offset by the higher gross profit.<br />
Liquidity and Capital Resources<br />
In May <strong>20</strong>08, to finance the acquisition of Drogasmil, we entered into a long-term loan with Scotiabank Inverlat for an aggregate amount of up to Ps. 1,210 million,<br />
which has to be repaid monthly at the TIIE rate plus 0.75 percentage points for a term of seven years, with a grace period of 12 months. As of December 31, <strong>20</strong>09, we had drawn the full<br />
amount un<strong>de</strong>r the loan. The obligations un<strong>de</strong>r such agreement were guaranteed by the Company and our subsidiary, Drogueros, S.A. <strong>de</strong> C.V.<br />
69